Partner News – I-Mab | Pioneering the Next Generation of Immuno-Oncology

About

Who We Are
A global innovative biotech company

Value Creation
Laser-focused on delivering innovative therapies to patients in need

Leadership Team
A world-class global leadership team

People & Culture
People are the cornerstone of our success

Commitment to ESG
Committed to the highest environmental, social and governance standards
Innovation

Science
Our cutting-edge science focuses on fine-tuning the immune network in cancer

Publications & Presentations
A compilation of our latest publications and presentations

Operations
An integrated research, development, manufacturing and commercialization strategy
Products

Product Pipeline
We have an innovative and advanced immuno-oncology clinical pipeline

Clinical Trials
We work closely with global investigators to carefully conduct and monitor clinical studies
Partnerships
News & Events

News
Our Latest News

Events
Our Latest Events

2021.07.09

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

2021.06.29

NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

2020.11.09

Genexine and NeoImmuneTech Announce Data Release for their Phase 1/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-Negative Breast Cancer

2020.06.22

Genexine, “Hyleukin-7 (GX-I7), US clinical trial approval for COVID-19 treatment for mild patients”